pipette
ESEspañol

Partially functional hypomorphic missense variants in BRCA2 are reduced penetrance pathogenic variants

Huaizhi Huang, Chunling Hu, Jie Na, Lisa N. Heppler, Andrew Goldfarb, Matthew T. Kucera, Timothy C. Simmons, Kevin L. Peterson, Olivia K. Rossman, Steven N. Hart, Rohan David Gnanaolivu, Amik Munankarmy, Mohamed Abozaid, Jamie D. Weyandt, Christen M. Csuy, Christina A. Seelaus, Colin C. Young, Kelly Fulk, Zahra Heidari, Paulo Cilas Morais Lyra Junior, Ronan E. Couch, Benjamin P. Persons, Yen Y. Tan, Katherine L. Nathanson, Tuya Pal, Erin Mundt, Rachid Karam, Tina F. Pesaran, Siddhartha Yadav, Susan M. Domchek, Álvaro N.A. Monteiro, Scott H. Kaufmann, Nicholas James Boddicker, Wenan Chen, Elisha Hughes, Marcy E. Richardson, Brennan James Decker, Fergus J. Couch

Peer-reviewed journalReal-world use

In the authors' words

Abstract Identification of partial loss-of-function (hypomorphic), reduced penetrance pathogenic missense variants (RPPVs) and assessment of the clinical relevance of these variants is needed for improved hereditary cancer risk estimation. Here we show that 70 candidate hypomorphic missense variants in the DNA-binding domain of BRCA2 reduce homologous recombination DNA repair activity and endogenous cell survival, decrease RAD51 foci formation, and increase sensitivity to Poly(ADP-ribose) polymerase inhibitors. The 34 “strong” hypomorphs with greatest effects on function are associated with moderate risks of female breast cancer and later ages of diagnosis than pathogenic variants (PVs), and 14 of these variants can be classified as “likely pathogenic” by integration of functional data into a ClinGen BRCA1/2 variant curation model. In addition, 32% of tumors with hypomorphic variants and corresponding loss of heterozygosity for BRCA2 display homologous recombination deficiency (HRD) compared to 83% of tumors with PVs and 7% with benign variants. These RPPVs represent a class of BRCA2 variants that have implications for the clinical management of carriers.

Main resultThe abstract does not state a limitation.

Appeared: Thursday, November 19. Nature Communications. Peer-reviewed journal.

DOI: 10.1038/s41467-026-79433-5